Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Organisation › Details

Bluebird Bio (Group)

With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline. *

 

Period Start 2014-06-16 existent
Products Industry gene therapy
  Industry 2 genome editing (gene editing)
Person Person Leschly, Nick (Bluebird Bio 201606 CEO)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 150 2nd Street
  City 02141 Cambridge, MA
  Tel +1-339-499-9300
    Address record changed: 2014-11-26
     
Basic data Employees n. a.
  Currency USD
  Cash 1,410,000,000 (2019-09-30)
     
    * Document for �About Section�: Lonza Group Ltd.. (6/9/16). "Press Release: Lonza and Bluebird Bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D and LentiGlobin Drug Products". Basel & Cambridge, MA.
     
   
Record changed: 2019-11-16

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Bluebird Bio (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top